Hyderabad becomes the world’s second-largest hub for innovation in pharma, biotech, and advanced therapeutics—outside the United States
From Regional Ambition to Global Recognition
In a remarkable transformation that underscores India’s rising prominence in global biotechnology and pharmaceuticals, Telangana’s life sciences ecosystem has achieved a landmark milestone, reaching an estimated valuation of $145 billion, fuelled by over ₹84,000 crore in investments over the past two years—the fastest expansion in the state’s history.
This achievement was formally announced during the 7th Board Meeting of the Telangana Life Sciences Foundation (TLSF), held in May 2026, marking a pivotal moment in the state’s transformation into a biotechnology superpower. The announcement signals that Hyderabad, once primarily known as India’s pharmaceutical hub, is now contending with the world’s leading life sciences clusters.
A Decade-Long Strategic Build-Up
The rapid acceleration of growth wasn’t accidental. The life sciences sector has expanded nearly threefold since 2016, establishing Hyderabad as one of the world’s premier life sciences clusters across pharmaceuticals, biotechnology, medical technology, and health tech innovation. However, the most dramatic gains came in the last 24 months, driven by focused policy initiatives and targeted investment strategies.
During the board meeting, former CEO Shakthi M. Nagappan presented insights from his decade-long tenure, characterizing the recent period as “a pivotal inflexion point” for the ecosystem. His presentation underscored the significance of institutional continuity under the dynamic leadership of Chief Minister A. Revanth Reddy and Industries & Commerce Minister D. Sridhar Babu. Recognizing Nagappan’s contributions to scaling the ecosystem, the government appointed him as Advisor (Lifesciences).
A Global Distinction: Nine of Ten Fortune Companies Present
Perhaps most striking among the ecosystem’s achievements is a claim to rare global distinction. Hyderabad now hosts technology and innovation centres from nine of the world’s top ten life sciences companies—the only region outside the United States with this distinction.
This concentration of multinational innovation and R&D infrastructure represents a fundamental shift in the geographic distribution of global life sciences power. The presence of these centers indicates that Hyderabad is no longer merely a manufacturing hub for generic pharmaceuticals, but a genuine innovation destination where breakthrough science is being conceived and developed.
“Key drivers include robust policy frameworks, strategic global partnerships, and targeted institution-building, cementing Telangana’s status as a highly integrated global ecosystem,” according to official statements highlighting the factors behind this achievement.
Next-Generation Vision: 2026-30 and Beyond
The milestone comes at a strategic inflection point for Telangana’s long-term ambitions. The Next-Gen Life Sciences Policy 2026–30 prioritizes frontier science and advanced manufacturing platforms, including cell and gene therapies, peptides, precision fermentation, and other next-generation modalities, strengthening the broader ecosystem across clinical research, pharma services, diagnostics, medical electronics and digital health.
This policy, unveiled at the World Economic Forum in Davos in January 2026, represents a deliberate scale-up from the state’s traditional pharmaceutical strengths. Rather than resting on its laurels as a generic drug manufacturer, Telangana is positioning itself at the frontiers of precision medicine, biotechnology innovation, and digital health solutions.
The state has set a target of drawing $25 billion in investments and generating 500,000 jobs in the sector by 2030—an ambitious goal that would require sustained momentum and continued policy support.
Infrastructure as Foundation: Genome Valley and Beyond
Critical to the ecosystem’s success is its physical infrastructure. Genome Valley, spread across roughly 2,000 acres on the city’s outskirts, hosts over 200 biotech and pharmaceutical companies from multiple countries and remains the anchor of the state’s life sciences ecosystem.
The government is now planning expansion at scale. Policy implementation will be anchored by globally benchmarked infrastructure, including the Green Pharma City, ten Pharma Villages, expansion of Genome Valley, and further strengthening of the Medical Devices Park. A dedicated Life Sciences Innovation Fund, scalable up to INR 1,000 crore (USD 100 million), will catalyze early- and growth-stage innovation, support deep-tech ventures, and crowd in private and institutional capital.
This multi-pronged infrastructure approach reflects a comprehensive strategy to support both established industry players and emerging startups, creating a diverse and resilient ecosystem.
Implications for Global Healthcare Innovation
Telangana’s emergence as a $145 billion life sciences ecosystem carries significant implications for global healthcare development. The concentration of both multinational R&D centers and domestic innovation capacity positions the region to participate actively in solving global health challenges—from rare disease therapeutics to pandemic preparedness.
The ecosystem’s focus on advanced manufacturing and frontier modalities—particularly cell and gene therapies and precision fermentation—aligns with where the global industry is moving. These technologies promise transformative treatments for previously incurable conditions, and Telangana’s investment in this space positions Indian researchers and manufacturers to be central players in this therapeutic revolution.
A Model for Emerging Biotech Ecosystems
What Telangana has achieved in less than a decade offers a template for other emerging economies seeking to build world-class life sciences infrastructure. The formula appears to combine stable policy frameworks, significant capital investment, strategic courting of multinational partnerships, and targeted development of specialized infrastructure clusters.
The appointment of a new CEO, Mr. Sarvesh Singh, signals continuity in leadership while also marking a new chapter. Board priorities for 2026-27 emphasize sustaining momentum while accelerating implementation of the Life Sciences Policy.
Looking Ahead: The Inflection Point
Industries Minister D. Sridhar Babu stated: “Telangana’s life sciences sector has witnessed unprecedented growth over the past two years. A focused ecosystem-building effort, anchored in strong institutional leadership and policy continuity has helped attract investments, forging global partnerships, and accelerating innovation and growth. We are at the cusp of the next phase of growth enabled by the initiatives in the Next Generation Life Sciences Policy”.
With significant commitments already grounded and additional investments in the Green Pharma City pipeline, Telangana appears well-positioned to achieve its 2030 targets. If the ecosystem continues its current trajectory, the region could establish itself not merely as a manufacturing hub, but as a genuine innovation leader shaping the future of global healthcare.
Rashmi Kumari
